Eledon Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals, Inc. in brief
Eledon Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Irvine, California, USA. Its market value was $257 M on 30 October 2026, which makes it the 15,375th largest listed company in the world and the 3,003rd largest in the USA on this site. It employs about 33 people and David-Alexandre C. Gros is its chief executive. Its shares trade under the symbol ELDN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Eledon Pharmaceuticals, Inc.
Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Our lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that we believe has broad therapeutic potential. We believe the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.
From the company's annual report filed with the US SEC: read the report
Eledon Pharmaceuticals, Inc. timeline
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2014
- 🔔Initial public offering as Tokai Pharmaceuticals IncFinal prospectus filed with the SEC on 18 September 2014; shares registered for exchange trading on 12 September 2014.
- 2017
- ✎Renamed Novus Therapeutics, Inc.Formerly Tokai Pharmaceuticals Inc.
- 2020
- ✎Renamed Eledon Pharmaceuticals, Inc.Formerly Novus Therapeutics, Inc..
Events of Eledon Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,023 (Dec 2022) · #5,026 (Jul 2023) · #4,092 (Jan 2024) · #1,778 (Mar 2026) · #2,929 (Aug 2026) · #3,145 (Oct 2026) · #3,007 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.2×
- Free cash flow yield
- -1.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -56.3%
- Liabilities / assets
- 19.1%
- Profit per employee
- $-1.4 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | — | $-46M | — |
| Dec 2024 | — | — | — | $-36M | — |
| Dec 2023 | — | — | $-43M | $-117M | — |
| Dec 2022 | — | — | $-88M | $-88M | — |
| Dec 2021 | — | — | $-37M | $-35M | — |
| Dec 2020 | — | — | $-18M | $-23M | — |
| Dec 2019 | — | — | $-16M | $-16M | — |
| Dec 2018 | — | — | $-14M | $-14M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-62M | — | — | $-0.52 | — |
| Dec 2024 | $-47M | — | — | $-0.66 | — |
| Dec 2023 | $-40M | — | — | $-4.73 | — |
| Dec 2022 | $-28M | — | — | $-6.16 | — |
| Dec 2021 | $-29M | — | — | $-2.33 | — |
| Dec 2020 | $-15M | — | — | $-15.72 | — |
| Dec 2019 | $-14M | — | — | $-24.42 | — |
| Dec 2018 | $-12M | — | — | $-1.56 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 22, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 30, 2026DEF 14AProxy statement
- Mar 19, 202610-KAnnual report · period to Dec 2025
- Mar 19, 20268-KCurrent reportResults of operations
- Jan 2, 20268-KCurrent reportUnregistered share sale
- Nov 14, 20258-KCurrent reportResults of operations
Official filings of Eledon Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- —
- Net income
- $-46 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $169 M
- Total liabilities
- $32 M
- Total equity
- $81 M
As of December-2025
Top 100 institutional investors in Eledon Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,641,297 | +1,517,455 (+29.62%) | 7.86% | $17 M | Nov 13, 2026 |
| 2 | BVF Inc/il | 6,293,282 | 0 (0.00%) | 7.45% | $16 M | Nov 16, 2026 |
| 3 | Defilade Capital Management, L.P. | 3,525,338 | 0 (0.00%) | 4.17% | $9 M | Nov 16, 2026 |
| 4 | Vanguard Capital Management LLC | 3,417,223 | 0 (0.00%) | 4.05% | $9 M | Nov 13, 2026 |
| 5 | Goldman Sachs Group Inc | 2,561,285 | +50,977 (+2.03%) | 3.03% | $6 M | Nov 16, 2026 |
| 6 | Geode Capital Management, LLC | 1,980,977 | +24,376 (+1.25%) | 2.35% | $5 M | Nov 6, 2026 |
| 7 | Ensign Peak Advisors, Inc | 1,756,223 | -345,001 (-16.42%) | 2.08% | $4 M | Nov 12, 2026 |
| 8 | Catalio Capital Management, LP | 1,637,114 | -57,957 (-3.42%) | 1.94% | $4 M | Nov 16, 2026 |
| 9 | State Street Corp | 1,614,898 | -7,071 (-0.44%) | 1.91% | $4 M | Nov 12, 2026 |
| 10 | Sphera Funds Management LTD. | 1,392,187 | +201,000 (+16.87%) | 1.65% | $4 M | Nov 16, 2026 |
| 11 | Zimmer Partners, LP | 1,200,000 | -396,599 (-24.84%) | 1.42% | $3 M | Nov 16, 2026 |
| 12 | AWM Investment Company, Inc. | 1,100,000 | 0 (0.00%) | 1.30% | $3 M | Nov 13, 2026 |
| 13 | Millennium Management LLC | 789,861 | -189,851 (-19.38%) | 0.94% | $2 M | Nov 16, 2026 |
| 14 | ADAR1 Capital Management, LLC | 652,812 | +5,000 (+0.77%) | 0.77% | $2 M | Nov 16, 2026 |
| 15 | 22NW, LP | 636,364 | 0 (0.00%) | 0.75% | $2 M | Nov 13, 2026 |
| 16 | Northern Trust Corp | 630,758 | +14,359 (+2.33%) | 0.75% | $2 M | Nov 16, 2026 |
| 17 | Vanguard Fiduciary Trust Co | 575,672 | +46,709 (+8.83%) | 0.68% | $1 M | Nov 13, 2026 |
| 18 | Blue Owl Capital Holdings LP | 566,509 | 0 (0.00%) | 0.67% | $1 M | Nov 13, 2026 |
| 19 | Renaissance Technologies LLC | 556,900 | +356,000 (+177.20%) | 0.66% | $1 M | Nov 12, 2026 |
| 20 | Vanguard Portfolio Management LLC | 542,676 | +9,311 (+1.75%) | 0.64% | $1 M | Nov 13, 2026 |
| 21 | UBS Group AG | 532,686 | -515,559 (-49.18%) | 0.63% | $1 M | Nov 10, 2026 |
| 22 | CM Management, LLC | 525,000 | -50,000 (-8.70%) | 0.62% | $1 M | Nov 12, 2026 |
| 23 | Dimensional Fund Advisors LP | 511,559 | -27,179 (-5.04%) | 0.61% | $1 M | Nov 4, 2026 |
| 24 | Jacobs Levy Equity Management, Inc | 484,760 | +374,919 (+341.33%) | 0.57% | $1 M | Nov 16, 2026 |
| 25 | BIT Capital GmbH | 427,000 | +161,000 (+60.53%) | 0.51% | $1 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Brevan Howard Capital Management LP | 381,447 | +76,740 (+25.18%) | 0.45% | $1 M | Nov 16, 2026 |
| 27 | Triumph Capital Management | 316,509 | +13,066 (+4.31%) | 0.37% | $1 M | Oct 14, 2026 |
| 28 | Bank Of America Corp /de/ | 307,463 | -575,634 (-65.18%) | 0.36% | $1 M | Nov 16, 2026 |
| 29 | Qube Research & Technologies Ltd | 271,051 | New | 0.32% | $1 M | Nov 13, 2026 |
| 30 | Morgan Stanley | 250,903 | -234,189 (-48.28%) | 0.30% | $1 M | Nov 13, 2026 |
| 31 | Charles Schwab Investment Management Inc | 247,406 | +2 (0.00%) | 0.29% | $1 M | Nov 16, 2026 |
| 32 | Nuveen, LLC | 224,041 | +14,944 (+7.15%) | 0.27% | $1 M | Nov 10, 2026 |
| 33 | Bank of New York Mellon Corp | 158,917 | -8,010 (-4.80%) | 0.19% | $0 M | Nov 5, 2026 |
| 34 | Susquehanna International Group, LLP | 144,158 | -108,074 (-42.85%) | 0.17% | $0 M | Nov 16, 2026 |
| 35 | Susquehanna Portfolio Strategies, LLC | 140,675 | +68,756 (+95.60%) | 0.17% | $0 M | Nov 16, 2026 |
| 36 | Russell Investments Group, Ltd. | 127,933 | +87,010 (+212.62%) | 0.15% | $0 M | Nov 6, 2026 |
| 37 | LPL Financial LLC | 122,055 | +10,360 (+9.28%) | 0.14% | $0 M | Nov 6, 2026 |
| 38 | FMR LLC | 95,110 | +88,875 (+1425.42%) | 0.11% | $0 M | Nov 10, 2026 |
| 39 | Daytona Street Capital LLC | 91,666 | +10,500 (+12.94%) | 0.11% | $0 M | Oct 15, 2026 |
| 40 | Rhumbline Advisers | 87,988 | -621 (-0.70%) | 0.10% | $0 M | Nov 10, 2026 |
| 41 | Prodigy Asset Management LLC | 86,703 | 0 (0.00%) | 0.10% | $0 M | Oct 28, 2026 |
| 42 | AQR Capital Management LLC | 76,215 | -504,813 (-86.88%) | 0.09% | $0 M | Nov 16, 2026 |
| 43 | Raymond James Financial Inc | 76,194 | +40,781 (+115.16%) | 0.09% | $0 M | Nov 12, 2026 |
| 44 | Farmers & Merchants Investments Inc | 74,123 | +67,802 (+1072.65%) | 0.09% | $0 M | Oct 22, 2026 |
| 45 | Rockefeller Capital Management L.P. | 72,666 | 0 (0.00%) | 0.09% | $0 M | Nov 13, 2026 |
| 46 | Public Employees Retirement System Of Ohio | 68,065 | New | 0.08% | $0 M | Nov 16, 2026 |
| 47 | Deutsche Bank AG\ | 67,170 | -9,473 (-12.36%) | 0.08% | $0 M | Nov 6, 2026 |
| 48 | Price T Rowe Associates Inc /MD/ | 63,984 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 49 | Invesco Ltd. | 58,237 | -1,060 (-1.79%) | 0.07% | $0 M | Nov 12, 2026 |
| 50 | PW Nova Financial Services LLC | 58,041 | 0 (0.00%) | 0.07% | $0 M | Oct 15, 2026 |
| 51 | Point72 Asset Management, L.P. | 53,247 | New | 0.06% | $0 M | Nov 16, 2026 |
| 52 | Ingalls & Snyder LLC | 51,849 | 0 (0.00%) | 0.06% | $0 M | Nov 12, 2026 |
| 53 | Simplex Trading, LLC | 46,866 | -41,731 (-47.10%) | 0.06% | $0 M | Nov 4, 2026 |
| 54 | Spark Investment Management LLC | 40,800 | New | 0.05% | $0 M | Nov 13, 2026 |
| 55 | Jump Financial, LLC | 40,708 | +19,427 (+91.29%) | 0.05% | $0 M | Nov 13, 2026 |
| 56 | Citigroup Inc | 39,013 | +2,935 (+8.14%) | 0.05% | $0 M | Nov 4, 2026 |
| 57 | Jpmorgan Chase & Co | 38,554 | +6,243 (+19.32%) | 0.05% | $0 M | Nov 12, 2026 |
| 58 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 37,366 | +1,893 (+5.34%) | 0.04% | $0 M | Nov 16, 2026 |
| 59 | Barclays PLC | 36,445 | +24,556 (+206.54%) | 0.04% | $0 M | Nov 6, 2026 |
| 60 | Vanguard Global Advisers, LLC | 36,083 | +11,147 (+44.70%) | 0.04% | $0 M | Nov 13, 2026 |
| 61 | Wells Fargo & Company/mn | 33,138 | -41,806 (-55.78%) | 0.04% | $0 M | Nov 16, 2026 |
| 62 | Alliancebernstein L.P. | 32,400 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 63 | Citadel Advisors LLC | 32,201 | -183,772 (-85.09%) | 0.04% | $0 M | Nov 16, 2026 |
| 64 | Jones Financial Companies Lllp | 30,833 | +10,881 (+54.54%) | 0.04% | $0 M | Nov 13, 2026 |
| 65 | Marco Investment Management LLC | 30,344 | 0 (0.00%) | 0.04% | $0 M | Nov 9, 2026 |
| 66 | Cetera Investment Advisers | 30,267 | +1,400 (+4.85%) | 0.04% | $0 M | Nov 13, 2026 |
| 67 | Retirement Planning Group, LLC | 30,001 | 0 (0.00%) | 0.04% | $0 M | Oct 19, 2026 |
| 68 | Howard Financial Services, LTD. | 30,000 | -30,000 (-50.00%) | 0.04% | $0 M | Oct 15, 2026 |
| 69 | MetLife Investment Management, LLC | 29,100 | -11,818 (-28.88%) | 0.03% | $0 M | Nov 16, 2026 |
| 70 | SEI Investments Co | 27,121 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 71 | Police & Firemen's Retirement System of New Jersey | 23,508 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 72 | Manufacturers Life Insurance Company, The | 22,537 | +1,086 (+5.06%) | 0.03% | $0 M | Nov 13, 2026 |
| 73 | BNP Paribas Financial Markets | 19,903 | +8,710 (+77.82%) | 0.02% | $0 M | Nov 12, 2026 |
| 74 | Commonwealth Equity Services, LLC | 19,754 | +3,198 (+19.32%) | 0.02% | $0 M | Nov 2, 2026 |
| 75 | Mariner, LLC | 17,615 | -32,426 (-64.80%) | 0.02% | $0 M | Nov 12, 2026 |
| 76 | China Universal Asset Management Co., Ltd. | 16,900 | +900 (+5.62%) | 0.02% | $0 M | Oct 28, 2026 |
| 77 | Cambridge Investment Research Advisors, Inc. | 16,830 | -103,060 (-85.96%) | 0.02% | $0 M | Nov 2, 2026 |
| 78 | Private Advisor Group, LLC | 16,390 | -5,370 (-24.68%) | 0.02% | $0 M | Nov 10, 2026 |
| 79 | Baker Ellis Asset Management LLC | 16,000 | 0 (0.00%) | 0.02% | $0 M | Oct 14, 2026 |
| 80 | Voya Investment Management LLC | 15,906 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 81 | Claro Advisors Inc. | 15,897 | New | 0.02% | $0 M | Nov 2, 2026 |
| 82 | Ancora Advisors LLC | 15,000 | New | 0.02% | $0 M | Nov 17, 2026 |
| 83 | Blair William & Co/il | 14,500 | -443 (-2.96%) | 0.02% | $0 M | Nov 10, 2026 |
| 84 | Neuberger Berman Group LLC | 14,360 | +1,114 (+8.41%) | 0.02% | $0 M | Nov 13, 2026 |
| 85 | Independent Advisor Alliance | 14,300 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 86 | Revolve Wealth Partners, LLC | 14,143 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 87 | Mercer Global Advisors Inc /adv | 13,987 | -19,512 (-58.25%) | 0.02% | $0 M | Nov 16, 2026 |
| 88 | XTX Topco Ltd | 13,814 | -24,493 (-63.94%) | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Signaturefd, LLC | 12,935 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 90 | Two Sigma Investments, LP | 12,638 | -20,307 (-61.64%) | 0.01% | $0 M | Nov 16, 2026 |
| 91 | Two Sigma Securities, LLC | 12,477 | New | 0.01% | $0 M | Nov 16, 2026 |
| 92 | Waverly Advisors, LLC | 12,256 | -1,596 (-11.52%) | 0.01% | $0 M | Nov 16, 2026 |
| 93 | Corient Private Wealth LP | 12,057 | -6,071 (-33.49%) | 0.01% | $0 M | Nov 16, 2026 |
| 94 | HUB Investment Partners, LLC | 11,746 | New | 0.01% | $0 M | Nov 3, 2026 |
| 95 | Prudential Financial Inc | 11,520 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 96 | Summit Financial, LLC | 11,500 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 97 | StoneX Group Inc. | 11,350 | New | 0.01% | $0 M | Nov 3, 2026 |
| 98 | Apollon Financial, LLC | 11,258 | New | 0.01% | $0 M | Oct 23, 2026 |
| 99 | Creative Planning | 11,104 | -12,355 (-52.67%) | 0.01% | $0 M | Nov 2, 2026 |
| 100 | Susquehanna Fundamental Investments, LLC | 10,975 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
Mutual funds holding Eledon Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 2.48 M | $10 M | 2.9% | <0.01% | +5.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 2.04 M | $8 M | 2.4% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 854,634 | $3 M | 1.0% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 723,407 | $3 M | 0.86% | 0.02% | +1730% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 839,205 | $3 M | 0.99% | <0.01% | +13% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 389,371 | $1 M | 0.46% | <0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 383,983 | $1 M | 0.45% | <0.01% | +39% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 311,993 | $1 M | 0.37% | 0.10% | +138% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 255,233 | $1 M | 0.30% | 0.07% | +36% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 286,012 | $1 M | 0.34% | 0.07% | −13% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 196,897 | $1 M | 0.23% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 187,417 | $1 M | 0.22% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 141,649 | $1 M | 0.17% | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 134,953 | $1 M | 0.16% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P. | 129,548 | $0 M | 0.15% | 0.13% | +151% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 111,465 | $0 M | 0.13% | <0.01% | +12% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 102,669 | $0 M | 0.12% | <0.01% | +35% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 85,200 | $0 M | 0.10% | <0.01% | −0.0% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 81,409 | $0 M | 0.10% | 0.14% | +328% | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 81,103 | $0 M | 0.10% | 0.15% | +954% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 92,156 | $0 M | 0.11% | <0.01% | +274% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 72,107 | $0 M | 0.09% | 0.02% | +1897% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 79,307 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 56,600 | $0 M | 0.07% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 57,445 | $0 M | 0.07% | <0.01% | +65% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 53,969 | $0 M | 0.06% | 0.02% | +35% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 59,987 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 54,836 | $0 M | 0.06% | <0.01% | +867% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 43,564 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 39,749 | $0 M | 0.05% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 45,699 | $0 M | 0.05% | <0.01% | +162% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 39,630 | $0 M | 0.05% | <0.01% | +734% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 35,863 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 38,593 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 33,007 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 36,789 | $0 M | 0.04% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 30,676 | $0 M | 0.04% | <0.01% | −31% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 30,905 | $0 M | 0.04% | <0.01% | +56% | May 31, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 33,800 | $0 M | 0.04% | 0.04% | new | Jul 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 25,778 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 25,500 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 23,250 | $0 M | 0.03% | <0.01% | −4.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 26,679 | $0 M | 0.03% | <0.01% | +3.0% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 22,071 | $0 M | 0.03% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 20,297 | $0 M | 0.02% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 17,403 | $0 M | 0.02% | <0.01% | +0.1% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 17,203 | $0 M | 0.02% | 0.03% | +30% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 16,769 | $0 M | 0.02% | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 16,200 | $0 M | 0.02% | <0.01% | +595% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 16,200 | $0 M | 0.02% | <0.01% | +595% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 17,666 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 15,125 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 12,370 | $0 M | 0.01% | 0.01% | +51% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 12,086 | $0 M | 0.01% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 11,592 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 11,550 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 13,360 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 10,768 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 10,548 | $0 M | 0.01% | <0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 10,360 | $0 M | 0.01% | 0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 11,861 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 11,587 | $0 M | 0.01% | <0.01% | +2.0% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 11,500 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 10,548 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 9,021 | $0 M | 0.01% | <0.01% | +51% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 8,519 | $0 M | 0.01% | <0.01% | +4.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 7,403 | $0 M | <0.01% | <0.01% | +74% | May 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 6,992 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 6,168 | $0 M | <0.01% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,160 | $0 M | <0.01% | <0.01% | +41% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 5,984 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 6,645 | $0 M | <0.01% | <0.01% | +2456% | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 5,546 | $0 M | <0.01% | 0.01% | +10% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 5,404 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 4,892 | $0 M | <0.01% | <0.01% | +61% | May 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,800 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 4,274 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 3,517 | $0 M | <0.01% | <0.01% | +45% | May 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 3,882 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 3,184 | $0 M | <0.01% | <0.01% | −33% | Jun 30, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 2,900 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 2,782 | $0 M | <0.01% | <0.01% | −20% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 2,750 | $0 M | <0.01% | <0.01% | −21% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,044 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 2,075 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 1,836 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,831 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,419 | $0 M | <0.01% | <0.01% | −12% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,307 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 1,103 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 359 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 91 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Eledon Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David-Alexandre C. GrosChief Executive Officer, Director | Grant or award | +354,454 | — | — | 363,454 | Form 4 |
| filed | Steven PerrinPresident, Director | Grant or award | +152,353 | — | — | 153,353 | Form 4 |
| filed | David-Alexandre C. GrosChief Executive Officer, Director | Shares withheld for tax | -194,791 | $3.380 | $658 K | 168,663 | Form 4 |
| filed | Steven PerrinPresident, Director | Shares withheld for tax | -72,138 | $3.380 | $244 K | 81,215 | Form 4 |
| filed | June LeeDirector | Option exercise | +3,430 | — | — | 3,430 | Form 4 |
| filed | Jan HillsonDirector | Option exercise | +3,430 | — | — | 3,430 | Form 4 |
| filed | John S. McBrideDirector | Option exercise | +3,430 | — | — | 3,430 | Form 4 |
| filed | James A. Robinson Jr.Director | Option exercise | +3,430 | — | — | 3,430 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Eledon Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-18 reverse split in the period to ; 1-for-9 reverse split in the period to ; 1-for-9 reverse split in the period to ; 1-for-10.53 reverse split
Fails to deliver
- : 8,641 shares at $3.04
- : 828 shares at $2.41
- : 2,000 shares at $2.26
- : 3,858 shares at $2.13
- : 3,596 shares at $2.25
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Eledon Pharmaceuticals, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.2×Price to book 3.2× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-1.9%Free cash flow is -1.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.52 vs -0.66Diluted EPS -0.52 in fiscal 2025 against -0.66 the year before (report's currency).
- ✗Net income higher than five years earlier-$46 M-$46 M in fiscal 2025 against -$23 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$46 MNet income -$46 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-63.6%-63.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities7.4×Current ratio 7.40 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year68.6%Diluted shares up 68.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Eledon Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | 0—— | |
| Research and development | 66+27.5%— | 52+71.4%— | 30+11.9%— | 27+14.1%— | 24+287%— | 6.1−24.6%— | 8.1+19.2%— | 6.8+237%— | 2.0−36.6%— | 3.2r25—— | |
| General and administrative | 17−8.8%— | 19+46.7%— | 13−0.1%— | 13−3.3%— | 13+30.6%— | 10+66.0%— | 6.1−16.4%— | 7.2−34.7%— | 11+473%— | 1.9r13—— | |
| Operating expenses | 83+18.0%— | 71+64.1%— | 43−51.4%— | 88+140%— | 37+99.7%— | 18+15.0%— | 16+14.2%— | 14+7.2%— | 13+156%— | 5.1r38—— | |
| Operating income | — | — | −43—— | −88—— | −37—— | −18—— | −16—— | −14—— | −13—— | −5.1r−38—— | |
| Other non-operating income (expense) | 4.2+7.5%— | 3.9+46.7%— | 2.7+479%— | 0.5+6500%— | 0.0−91.1%— | 0.1+97.5%— | 0.0—— | −0.0−200%— | 0.0—— | −0.5—— | |
| Income before tax | −46—— | −36—— | −117r−40—— | −88—— | −37—— | −23—— | −16—— | −14—— | −13—— | −5.7—— | |
| Income tax | 0.0−91.9%— | 0.4—— | 0—— | 0—— | −2.4—— | −0.4—— | — | — | — | 0—— | |
| Net income attributable to shareholders | −46—— | −36—— | −117r−40—— | −88—— | −35—— | −23—— | −16—— | −14—— | −13—— | −5.7r−38—— | |
| Earnings per share, basic | -0.52—— | -0.66r-0.75—— | -4.73r-1.64—— | -6.16—— | -2.33—— | -15.72—— | -24.42r-1.36—— | -1.56—— | -2.30—— | -2.46r-1.68—— | |
| Earnings per share, diluted | -0.52—— | -0.66r-0.75—— | -4.73r-1.64—— | -6.16—— | -2.33—— | -15.72—— | -24.42r-1.36—— | -1.56—— | -2.30—— | -2.46r-1.68—— | |
| Shares, weighted average (basic) | 82+68.6%— | 49+97.2%— | 25+72.3%— | 14−3.6%— | 15—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 82+68.6%— | 49+97.2%— | 25+72.3%— | 14−3.6%— | 15+921%— | 1.5+121%— | 0.7r12−92.7%— | 9.0+92.5%— | 4.7+1122%— | 0.4r23—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 23+11.0%13.5% | 21+346%11.6% | 4.6−91.8%5.2% | 56−33.5%60.8% | 85−25.7%49.7% | 114+1199%57.9% | 8.8−32.2%80.4% | 13−24.7%76.2% | 17+1462%82.5% | 1.1r23—92.2% | |
| Short-term investments | 111−7.6%65.4% | 120+157%67.4% | 46—52.2% | 0—0.0% | — | — | — | — | — | — | |
| Other current assets | 0.0−89.4%0.0% | 0.1r0.7+15.6%0.1% | 0.1+221%0.1% | 0.0−17.6%0.0% | 0.0−10.5%0.0% | 0.0−29.6%0.0% | 0.1+50.0%0.5% | 0.0r0.6+100%0.2% | 0.0−45.5%0.1% | 0.0r2.0—2.8% | |
| Current assets | 136−5.6%80.3% | 144+156%81.0% | 56−5.7%63.0% | 60−32.6%64.1% | 88−23.6%51.8% | 116+1060%58.6% | 10.0−30.2%91.2% | 14−24.9%83.8% | 19+1552%90.9% | 1.2r30—96.2% | |
| Property, plant and equipment | — | — | — | — | — | — | 0.0−64.3%0.0% | 0.0−44.0%0.1% | 0.0−19.4%0.1% | 0.0r0.1—2.6% | |
| Right-of-use (leased) assets | 0.6−33.8%0.4% | 0.9+154%0.5% | 0.4−50.6%0.4% | 0.7−3.8%0.8% | 0.8+457%0.5% | 0.1−56.3%0.1% | 0.3—2.9% | — | — | — | |
| Goodwill | — | — | 0—0.0% | 0−100%0.0% | 490.0%28.5% | 49—24.7% | — | 1.90.0%11.0% | 1.9—8.9% | — | |
| Total assets | 169−4.7%100% | 177+99.2%100% | 89−4.0%100% | 93−45.6%100% | 171−13.5%100% | 197+1704%100% | 11−35.8%100% | 17−18.5%100% | 21+1647%100% | 1.2r30—100% | |
| Accounts payable | 3.6−37.8%2.1% | 5.8+503%3.3% | 1.0−56.0%1.1% | 2.2+21.3%2.4% | 1.8+32.7%1.1% | 1.4+315%0.7% | 0.3−52.2%3.0% | 0.7+64.8%4.0% | 0.4+23.7%2.0% | 0.3r0.4—28.3% | |
| Current liabilities | 18+58.5%10.9% | 12+197%6.5% | 3.9−39.8%4.4% | 6.5+47.1%7.0% | 4.4+77.2%2.6% | 2.5+87.8%1.3% | 1.3−47.8%12.1% | 2.5—14.9% | — | 3.9r2.8—326% | |
| Lease liabilities (non-current) | 0.3−55.8%0.2% | 0.6—0.4% | 0−100%0.0% | 0.4−4.2%0.4% | 0.4—0.2% | — | 0.1—1.3% | — | — | — | |
| Non-current liabilities | — | — | — | — | — | — | — | — | — | 0.1—7.0% | |
| Total liabilities | 32−45.6%19.1% | 59−27.6%33.4% | 82r5.6+851%91.9% | 8.6+31.4%9.3% | 6.6−0.5%3.8% | 6.6+349%3.3% | 1.5−42.1%13.4% | 2.5+76.0%14.9% | 1.4−63.1%6.9% | 3.9r2.9—326% | |
| Retained earnings | −401—−237% | −356—−200% | −319r−243—−359% | −203—−219% | −115—−67.4% | −80—−40.8% | −58—−527% | −42—−244% | −28—−132% | −14r−169—−1203% | |
| Shareholders' equity | 81+29.8%48.0% | 62r118—35.2% | −48r83−304%−54.4% | 24r84−85.5%25.6% | 164−14.0%96.2% | 191+1914%96.7% | 9.5−34.7%86.6% | 14−25.5%85.1% | 19—93.1% | −2.7r27—−226% | |
| Total liabilities and equity | 169−4.7%100% | 177+99.2%100% | 89−4.0%100% | 93−45.6%100% | 171−13.5%100% | 197+1704%100% | 11−35.8%100% | 17−18.5%100% | 21+1647%100% | 1.2r30—100% | |
| Shares outstanding | 75+26.2%— | 60+147%— | 24+75.8%— | 14−3.7%— | 14−5.6%— | 15+2004%— | 0.7r13−92.4%— | 9.4+32.5%— | 7.1+1703%— | 0.4r23—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | 0.0−44.4%— | 0.0−18.2%— | 0.0−50.0%— | 0.0−37.1%— | 0.0—— | |
| Share-based compensation | 10−20.4%— | 13+100%— | 6.5−19.7%— | 8.2+3.2%— | 7.9+149%— | 3.2+142%— | 1.3−15.2%— | 1.5+166%— | 0.6+239%— | 0.2r3.0—— | |
| Cash from operating activities | −62—— | −47—— | −40—— | −28—— | −29—— | −15—— | −14—— | −12—— | −15—— | −4.9r−37—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | −0.0r−0.0—— | |
| Cash from investing activities | 11—— | −70—— | −45—— | — | — | 11—— | — | — | 23+2325700%— | 0.0r36—— | |
| Shares issued | — | — | — | — | — | 9.0−7.0%— | 9.7+29.2%— | 7.5+57.7%— | 4.8—— | — | |
| Cash from financing activities | 54−59.7%— | 134+304%— | 33—— | — | −0.4−100%— | 110+1033%— | 9.7+28.0%— | 7.6−3.9%— | 7.9+169%— | 2.9r0.0—— | |
| Change in cash | 2.3−85.8%— | 16—— | −52—— | −28—— | −29−128%— | 105—— | −4.2—— | −4.3−127%— | 16—— | −2.0r−0.8—— | |
| Report | 10-K | 10-K | 10-K/A | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 71+6.0%— | 18+18.7%— | 18−10.1%— | 17+27.1%— | 17*−2.4%— | 15−9.4%— | 20+101%— | 14+82.6%— | 18*+154%— | 17—— | 10—— | 7.4—— | 7.1*—— | |
| General and administrative | 17−16.4%— | 3.9−4.6%— | 4.6+4.1%— | 4.0−10.1%— | 4.0*−41.0%— | 4.1+2.8%— | 4.5+1.4%— | 4.4+28.2%— | 6.8*+107%— | 4.0—— | 4.4—— | 3.5—— | 3.3*—— | |
| Operating expenses | 87+0.9%— | 22+13.6%— | 23−7.5%— | 21+17.9%— | 21*−13.0%— | 19−7.0%— | 25+70.5%— | 18+65.3%— | 25*+139%— | 21—— | 15—— | 11—— | 10*—— | |
| Operating income | — | −22—— | −23—— | −21—— | — | −19—— | −25—— | −18—— | — | −21—— | −15—— | −11—— | −10*—— | |
| Other non-operating income (expense) | 3.2−36.8%— | 0.7−31.8%— | 0.9−29.6%— | 1.1−20.7%— | 0.5*−62.5%— | 1.0+0.5%— | 1.2+40.9%— | 1.4+145%— | 1.4*+102%— | 1.0—— | 0.9—— | 0.6—— | 0.7*—— | |
| Net income attributable to shareholders | −85—— | −3.9—— | −32—— | −39—— | −10*—— | −17−123%— | −11—— | −6.5—— | −45*—— | 77—— | −45—— | −24r−10—— | −30r−9.6*—— | |
| Earnings per share, basic | — | -0.03—— | -0.27—— | -0.33—— | — | -0.21−120%— | -0.13—— | -0.08—— | — | 1.05—— | -0.92r-1.06—— | -0.65r-0.34—— | — | |
| Earnings per share, diluted | — | -0.03—— | -0.27—— | -0.33—— | — | -0.21—— | -0.13—— | -0.08—— | — | -0.28r-0.32—— | -0.92r-1.06—— | -0.65r-0.34—— | — | |
| Shares, weighted average (basic) | 115+48.7%— | 115+48.7%— | 114+47.3%— | 112+45.8%— | — | 77+48.5%— | 77+82.5%— | 77+157%— | — | 52—— | 42—— | 30—— | — | |
| Shares, weighted average (diluted) | 115+48.7%— | 115+48.7%— | 114+47.3%— | 112+45.8%— | — | 77+39.1%— | 77+82.5%— | 77+157%— | — | 55—— | 42—— | 30—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.9—6.5% | 6.9+87.6%6.5% | 6.8+18.5%5.4% | 6.2−27.6%4.2% | 23+11.0%13.5% | 3.7−45.7%2.8% | 5.7−78.0%4.0% | 8.5+50.2%5.3% | 21+346%11.6% | 6.8—5.9% | 26—21.6% | 5.7—7.0% | 4.6—5.2% | |
| Short-term investments | 63—58.9% | 63−30.0%58.9% | 82−19.5%65.0% | 105−9.8%71.5% | 111−7.6%65.4% | 90+25.6%69.1% | 102+76.9%70.3% | 116+213%72.2% | 120+157%67.4% | 71—62.4% | 58—47.8% | 37—46.0% | 46—52.2% | |
| Other current assets | 0.5—0.5% | 0.5+3450%0.5% | 0.4+3720%0.3% | 0.0−83.6%0.0% | 0.0−89.4%0.0% | 0.0−96.8%0.0% | 0.0−93.6%0.0% | 0.1+1.9%0.0% | 0.1r0.7+15.6%0.1% | 0.4—0.4% | 0.2—0.1% | 0.1—0.1% | 0.1—0.1% | |
| Current assets | 74—69.1% | 74−23.5%69.1% | 93−16.4%73.8% | 114−11.1%77.4% | 136−5.6%80.3% | 96+18.1%74.2% | 111+27.7%76.9% | 128+166%79.2% | 144+156%81.0% | 82—71.1% | 87—72.4% | 48—59.4% | 56—63.0% | |
| Right-of-use (leased) assets | 0.4—0.3% | 0.4−48.4%0.3% | 0.4−42.4%0.4% | 0.5−37.6%0.4% | 0.6−33.8%0.4% | 0.7+47.3%0.5% | 0.8+24.5%0.5% | 0.9+215%0.5% | 0.9+154%0.5% | 0.5—0.4% | 0.6—0.5% | 0.3—0.3% | 0.4—0.4% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Total assets | 107—100% | 107−17.9%100% | 126−13.0%100% | 147−9.1%100% | 169−4.7%100% | 130+13.3%100% | 145+20.3%100% | 161+99.6%100% | 177+99.2%100% | 115—100% | 120—100% | 81—100% | 89—100% | |
| Accounts payable | 2.8—2.7% | 2.8−38.6%2.7% | 3.2−44.9%2.5% | 6.6+127%4.5% | 3.6−37.8%2.1% | 4.6−21.0%3.6% | 5.8+171%4.0% | 2.9+55.6%1.8% | 5.8+503%3.3% | 5.9—5.1% | 2.1—1.8% | 1.9—2.3% | 1.0—1.1% | |
| Current liabilities | 12—11.0% | 12−18.1%11.0% | 12−14.1%9.3% | 13+46.5%9.2% | 18+58.5%10.9% | 14+14.5%11.0% | 14+128%9.5% | 9.2+116%5.7% | 12+197%6.5% | 12—10.9% | 6.0—5.0% | 4.2—5.3% | 3.9—4.4% | |
| Lease liabilities (non-current) | 0.0—0.0% | 0.0−90.7%0.0% | 0.1−81.6%0.1% | 0.2−66.5%0.1% | 0.3−55.8%0.2% | 0.4+19.4%0.3% | 0.5+21.0%0.3% | 0.6—0.3% | 0.6—0.4% | 0.3—0.3% | 0.4—0.3% | 0—0.0% | 0—0.0% | |
| Total liabilities | 37—34.5% | 37−5.1%34.5% | 54+39.0%42.9% | 46−1.1%31.5% | 32−45.6%19.1% | 39+0.7%29.9% | 39−69.9%26.8% | 47−51.1%29.0% | 59−27.6%33.4% | 39—33.6% | 129—107% | 96r6.0—118% | 82r5.6—91.9% | |
| Retained earnings | −476—−446% | −476—−446% | −472—−374% | −440—−300% | −401—−237% | −391—−301% | −373—−258% | −362—−224% | −356—−200% | −311—−271% | −388—−322% | −343r−253—−424% | −319r−243—−359% | |
| Shareholders' equity | 31—28.9% | 31−12.9%28.9% | 33−34.4%26.2% | 45−24.0%30.5% | 81+29.8%48.0% | 35+73.6%27.2% | 50—34.7% | 59r115—36.5% | 62r118—35.2% | 20r76—17.8% | −64r−8.5—−53.3% | −70r75—−87.1% | −48r83—−54.4% | |
| Total liabilities and equity | 107—100% | 107−17.9%100% | 126−13.0%100% | 147−9.1%100% | 169−4.7%100% | 130+13.3%100% | 145+20.3%100% | 161+99.6%100% | 177+99.2%100% | 115—100% | 120—100% | 81—100% | 89—100% | |
| Shares outstanding | 81—— | 81+36.0%— | 81+35.1%— | 76+26.7%— | 75+26.2%— | 60+45.4%— | 60+55.5%— | 60+141%— | 60+147%— | 41—— | 39—— | 25—— | 24—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 9.7−33.1%— | 1.9−20.8%— | 3.2+17.1%— | 2.2−23.1%— | 2.5*−62.5%— | 2.4+36.2%— | 2.7−12.0%— | 2.9+69.1%— | 6.6*+285%— | 1.8—— | 3.1—— | 1.7—— | 1.7*—— | |
| Cash from operating activities | −78—— | −19*—— | −23*—— | −23—— | −14*—— | −14*—— | −18*—— | −16—— | −19*—— | −12*—— | −7.8*—— | −8.7—— | −9.1*—— | |
| Cash from investing activities | 28—— | 19*+55.8%— | 23*+55.3%— | 6.0+53.0%— | −20*—— | 12*—— | 15*—— | 3.9−60.2%— | −47*−570%— | −13*—— | −20*—— | 9.8—— | 10*—— | |
| Cash from financing activities | — | −0.3*—— | — | — | 54*−33.0%— | 0*−100%— | 0*−100%— | 0.1+11400%— | 80*—— | 5.3*—— | 48*—— | 0.0—— | 0*—— | |
| Change in cash | 3.2—— | 0.1*—— | 0.7*—— | −17—— | 19*+38.7%— | −2.1*—— | −2.8*−114%— | −12−1256%— | 14*+1360%— | −19*—— | 20*—— | 1.0—— | 0.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q/A | 10-K/A | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Eledon Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Gros | $3.2 M | −$315 K | $1.6 M | $66 |
| 2024David-Alexandre C. Gros | $5.6 M | $6.8 M | $3.8 M | $181 |
| 2023David-Alexandre C. Gros | $2.6 M | $405 K | $1.4 M | $79 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Eledon Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Financial statements withdrawn 2 · Auditor changed 3 · Directors and officers 1 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawnResults announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K/A | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Financial statements withdrawnResults announced | 8-K | |
| Auditor changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 acquisitions · 3 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Anelixis | Sep 2020 | Sep 2020 | — | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2024 | $50 M | Private placement after listing | $50 to $250 million | 24 | equity, options | SEC |
| May 2023 | $35 M | Private placement after listing | $10 to $50 million | 38 | equity, options | SEC |
| Sep 2020 | $108 M | Private placement after listing | $50 to $250 million | 35 | equity | SEC |
| May 2013 | $20 M | No. 3 | $10 to $50 million | 19 | equity | SEC |
| Sep 2011 | $2 M | No. 2 | Under $2 million | 6 | equity | SEC |
| May 2009 | $10 M | No. 1 | $10 to $50 million | 10 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2016 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Eledon Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$257 M · higher than 48% of 726
- Price / book3.2× · lower than 47% of 534
- FCF yield-1.9% · higher than 82% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Eledon Pharmaceuticals, Inc.🇺🇸 | $257 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 13, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Eledon Pharmaceuticals, Inc.? Verify and update this profile — free
Show Eledon Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.